Heterozygous Germline ATM Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease PURPOSE: To examine the safety, efficacy, costs, and impact on quality of life of ...
Add Yahoo as a preferred source to see more of our stories on Google. PorTal Access has secured FDA clearance for its range of implantable vascular access ports in the FLEXI-PORT family. Credit: ...
MIAMI, May 18, 2026 /PRNewswire/ -- PorTal Access, Inc., a medical device company pioneering next-generation vascular access solutions for oncology, today announced the successful completion of its ...
For the more than 870,000 patients in the U.S. being treated for end-stage renal disease, hemodialysis treatments become part of a daily or multiple-times-a-week routine. In order to perform dialysis, ...
MIAMI, June 22, 2026 /PRNewswire/ -- PorTal Access, Inc., an innovative medical device company advancing vascular access technologies, today announced that the U.S. Food and Drug Administration (FDA) ...
ST. PAUL, Minn.--(BUSINESS WIRE)--Every vascular catheter used on a patient poses potential for a costly and prevalent central line-associated bloodstream infection (CLABSI). Passive disinfection caps ...
Intravascular catheterization access for injection and sampling is one of the most common experimental surgical procedures.Catheters and ports have been designed to reduce the problems of occlusion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results